21-Dehydro Budesonide(CAS: 85234-63-5)

21-Dehydro Budesonide (CAS: 85234-63-5) falls under stringent regulatory guidelines including GHS classification for hazardous substances, REACH registration for European manufacturers, FDA requirements for drug approval, and EPA regulations for environmental safety. It is classified as a corticosteroid, necessitating compliance with specific handling, storage, and disposal protocols.

Alternatives to 21-Dehydro Budesonide (CAS: 85234-63-5) in synthesis include other corticosteroids like Budesonide itself and its analogs such as rimoxinone. Substitutes like cortisone and prednisone can also be used, though they may differ in potency and pharmacokinetics. Isomers and structural analogs are also explored for potential therapeutic applications.

The market for 21-Dehydro Budesonide (CAS: 85234-63-5) is growing due to its anti-inflammatory and immunosuppressive properties, making it widely used in respiratory and gastrointestinal treatments. Research trends focus on optimizing its delivery methods, exploring its role in chronic diseases, and investigating its potential as a topical treatment to reduce systemic side effects. Price trends reflect increasing demand, particularly in developing countries where respiratory diseases are more prevalent.

Waste containing 21-Dehydro Budesonide (CAS: 85234-63-5) should be collected in appropriate containers and stored in a secure, well-ventilated area. For disposal, it is recommended to use a professional hazardous waste management service that adheres to local regulations. Incineration is a common method, but measures must be taken to prevent release of pollutants. Environmental protection precautions include ensuring proper containment and neutralization of any residual compounds before disposal to minimize ecological impact.